serotonin-norepinephrine reuptake inhibitor


Also found in: Dictionary, Wikipedia.
Related to serotonin-norepinephrine reuptake inhibitor: SSNRI

serotonin-norepinephrine reuptake inhibitor

n.
An SNRI.

serotonin-norepinephrine reuptake inhibitor

Clinical pharmacology Any of a class of antidepressants–eg, venlafaxine, that block the reuptake of serotonin and norepinephrine
References in periodicals archive ?
Dosage forms 10 mg, 20 mg, and 40 mg tablets Starting 10 mg/d dosage Target dosage 40 mg/d Table 2 Fast facts: Levomilnacipran Brand name Fetzima Class Serotonin-norepinephrine reuptake inhibitor FDA approval July 26, 2013 date Manufacturer Forest Pharmaceuticals, Inc.
(1) The drug is the fifth serotonin-norepinephrine reuptake inhibitor (SNRI) to be sold in the United States and the fourth to receive FDA approval for treating MDD.
The manufacturer of desvenlafaxine will conduct a 1-year study aimed at resolving cardiovascular and hepatic safety concerns raised by the Food and Drug Administration in an "approvable" letter for the serotonin-norepinephrine reuptake inhibitor. Desvenlaxaine is under review as a treatment for menopausal hot flashes and night sweats.
Sibutramine is a serotonin-norepinephrine reuptake inhibitor that is marketed as Meridia by Abbott Laboratories.
Desvenlafaxine for major depressive disorder: incremental clinical benefits from a second-generation serotonin-norepinephrine reuptake inhibitor. Expert Opin Drug Metab Toxicol.
Sibutramine is a serotonin-norepinephrine reuptake inhibitor marketed as Meridia by Abbott Laboratories.
The FDA approved this selective serotonin-norepinephrine reuptake inhibitor (SNRI)--a major active metabolite of venlafaxine--for treating major depressive disorder (MDD, Table 1).
The reductions in mortality risk differed across categories of ATDs: selective serotonin reuptake inhibitors (HR, 0.63; 95 percent CI, 0.56 to 0.71), serotonin-norepinephrine reuptake inhibitors (HR, 0.58; 95 percent CI, 0.44 to 0.78), norepinephrine-dopamine reuptake inhibitors (HR, 0.20; 95 percent CI, 0.07 to 0.63), mirtazapine (HR, 0.60; 95 percent CI, 0.45 to 0.82), tricyclic/tetracyclic antidepressants (HR, 0.73; 95 percent CI, 0.54 to 0.97), and trazodone (HR, 0.52; 95 percent CI, 0.29 to 0.91).
Minerva announced results from a Phase 2b clinical trial of seltorexant as adjunctive therapy to antidepressants in adult patients with major depressive disorder, or MDD, who have responded inadequately to selective serotonin reuptake inhibitors, or SSRIs, and/or serotonin-norepinephrine reuptake inhibitors, or SNRIs.
The anti-depression medications included monoamine oxidase inhibitors (MAOIs), selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), tricyclics (TCAs) and non-classified ADMs.
PRISTIQ is in a class of medications known as SNRIs, or serotonin-norepinephrine reuptake inhibitors.